Work

Plasma Biomarkers for Alzheimer’s Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies

Year: 2026

Type: review

Abstract: Alzheimer's disease (AD) is the most common cause of dementia, and its overall incidence is rising as the proportion of older individuals in the population increases. Traditional diagnostic methods, such as lumbar puncture and neuroimaging, are costly and invasive, driving the search for blood-based biomarkers (BBB) for early diagnosis. The quantification of these biomarkers requires ultrasensitive techniques, such as the single-molecule array (SIMOA) platform. This systematic review synthesizes the available evidence on the biomarkers β-amyloid (Aβ42, Aβ40, and their ratio), tau protein (t-Tau, p-Tau181, p-Tau231, p-Tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in studies analyzing their blood concentrations using SIMOA, regardless of the platform model (SR-X, HD-1, HD-X). Findings support the potential of plasma biomarkers as an alternative or complement to invasive methods, although further validation is required before clinical implementation.

Source: Cellular and Molecular Neurobiology

DOI: 10.1007/s10571-026-01752-4

Authors: María de los Ángeles Fernández-Ceballos, José M. Prieto-González, Roberto Carlos Agís-Balboa

Institutions: Universidade de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago, Instituto de Investigación Sanitaria de Santiago, Servicio Gallego de Salud

Language: English

Topic: Dementia and Cognitive Impairment Research

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,590